ESC 365 - What proportion of patients with HFrEF might be candidates for Sacubitril-Valsartan?

HFA Premium Access

What proportion of patients with HFrEF might be candidates for Sacubitril-Valsartan?

Session: Moderated Poster session 3 - Novel treatment

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Doctor T. O connor (Dublin 9, IE)

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Doctor Tim O connor

Beaumont Hospital, Dublin 9 (Ireland)

1 presentation

0 follower

6 more presentations in this session

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

Heart failure patients with reduced left ventricular ejection fraction, who reached 100% target dose of beta-blockers in randomized and observational studies

Speaker: Mrs M. Oyanguren Artola (Bilbao, ES)

Metabolic response to exercise training in heart failure with preserved ejection fraction

Speaker: Doctor M. Bahls (Greifswald, DE)

Adherence to ESC guidelines after hospital admission for heart failure in 22500 Dutch patients: 2001-2015

Speaker: Mrs W. Kruik-Kolloffel (Almelo, NL)

Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure

Speaker: Doctor S. Zheng (London, GB)

Access the full session

Moderated Poster session 3 - Novel treatment

Speakers: Doctor T. O connor, Mrs M. Oyanguren Artola, Doctor M. Bahls, Mrs W. Kruik-Kolloffel, Doctor S. Zheng

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources